Lv1
20 积分 2025-04-18 加入
Engineering T Cells with a Tumor-Reactive Chimeric T Cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses
20小时前
已完结
The Time for Cancer Vaccines Is Now
5天前
已关闭
Efficacy and safety of boron neutron capture therapy for locally recurrent head and neck cancer
7天前
已完结
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China
7天前
已完结
‘They don’t have symptoms’: CAR-T therapies send autoimmune diseases into remission
8天前
已完结
Personalized Cancer Vaccine Shows Durable Benefit at 5 Years
13天前
已完结
Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial
15天前
已完结
Proton beam therapy for recurrent ovarian carcinoma: A case report
1个月前
已完结
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT
1个月前
已完结
Programmable oncolytic viruses for systemic cancer therapy
1个月前
已完结
皖公网安备34019202002308
